Biotech Startup Secures $30 Million to Research Gene-Edited Babies Despite Scientific Opposition
核心洞察
West Coast biotech entrepreneur Lucas Harrington has secured $30 million to launch Preventive (搜索), a public-benefit company focused on researching heritable genome editing for disease prevention.
The venture aims to study whether genetically editing embryos can be done safely by correcting harmful mutations or installing beneficial genes, with estimated costs of $5,000 per embryo.
Leading gene-editing experts strongly oppose such ventures, with UC Berkeley's Fyodor Urnov calling them dangerous and misguided distractions from proven therapeutic applications.
A West Coast biotech entrepreneur has secured $30 million to launch what he claims is the largest known investment into developing genetically edited babies, despite widespread scientific opposition to the controversial technology.
Lucas Harrington, a gene-editing scientist and cofounder of Mammoth Biosciences (搜索), announced the formation of Preventive (搜索), a public-benefit company dedicated to researching "heritable genome editing." The technology would modify embryo DNA by correcting harmful mutations or installing beneficial genes to prevent disease in future generations.
Third US Startup to Enter Controversial Field
Preventive (搜索) represents the third US startup this year to pursue gene-edited baby technology. Bootstrap Bio (搜索), based in California, is reportedly seeking seed funding with an interest in enhancing intelligence, while Manhattan Genomics (搜索) remains in formation stages without announced funding.
Harrington emphasized that Preventive (搜索) will not rush to implement the technique but will instead focus on "rigorously researching whether heritable genome editing can be done safely and responsibly." The company was incorporated in Delaware in May 2025 as Preventive Medicine PBC, structured as a public-benefit corporation to prioritize its public mission over profits.
Scientific Community Remains Skeptical
The venture faces significant opposition from established gene-editing experts. Fyodor Urnov, a gene-editing specialist at the University of California, Berkeley where Harrington studied, described the launch as making him want to "howl with pain."
Urnov has been a pointed critic of heritable genome editing, calling it "dangerous, misguided, and a distraction from the real benefits of gene editing to treat adults and children." When Manhattan Genomics (搜索) approached him about collaboration, Urnov responded: "I encourage you to stop. You will cause zero good and formidable harm."
Limited Scientific Endorsement
Despite seeking endorsements from leading genome editing figures, Preventive (搜索) has secured only one advisor: Paula Amato, a fertility doctor at Oregon Health Sciences University (搜索). Amato is part of a US team that has researched embryo editing since 2017 and has promoted the technology as a way to increase IVF success rates by correcting abnormal embryos.
The company was unsuccessful in establishing collaboration with at least one key research group, highlighting the broader scientific community's reluctance to engage with such ventures.
Funding Sources and Cost Projections
Harrington declined to identify most investors beyond SciFounders (搜索), a venture firm he runs with Matt Krisiloff, CEO of biotech company Conception (搜索). Krisiloff, who aims to create human eggs from stem cells, is listed as a member of Preventive (搜索)'s founding team.
The funding has attracted attention from cryptocurrency business figures, including Coinbase founder Brian Armstrong, who has hosted off-the-record dinners to discuss the technology. Armstrong previously argued that the "time is right" for a startup venture in this area.
Harrington estimates that editing an embryo would cost approximately $5,000 and believes regulations could change in the future to permit the technology.
Regulatory and Ethical Challenges
Creating genetically edited humans remains illegal in many countries, including the United States. The first scientist to create gene-edited babies, He Jiankui in China, was imprisoned for three years following his controversial experiments.
Harrington acknowledged the regulatory hurdles, stating that if research shows heritable genome editing "cannot be done safely, that conclusion is equally valuable to the scientific community and society."
Broader Context of Human Enhancement
The venture operates within a growing ecosystem of "human enhancement companies." Harrington's fund has invested in Herasight (搜索), a company using genetic tests to rank IVF embryos for future IQ and other traits—technology that has already reached market due to limited regulation.
Harrington believes most scientists either accept embryo editing as inevitable or are enthusiastic about its potential but hesitate to voice these opinions publicly. "Part of being more public about this is to encourage others in the field to discuss this instead of ignoring it," he said.
Despite the significant funding, none of the three US startups pursuing gene-edited baby technology have established significant staff, facilities, or credibility among mainstream gene-editing scientists, raising questions about their ability to conduct the rigorous research required for such a consequential technology.